改进CAR-T细胞有效性和安全性的设计策略

发布时间：2018-04-14 23:32

  本文选题：CAR-T细胞 + 设计策略　； 参考：《中国肿瘤生物治疗杂志》2017年05期

【摘要】：嵌合抗原受体T(chimeric antigen receptor T cells,CAR-T)细胞已从实验室走向了临床试验,在治疗B细胞恶性肿瘤中取得了显著疗效,但在探索CAR-T细胞治疗恶性肿瘤的临床研究中,仍面临不少困难与挑战:难以找到肿瘤特异性的靶点,以克服其脱靶效应(on-target off tumor effect);在治疗实体瘤中CAR-T细胞很难达到肿瘤部位,以改善免疫抑制微环境发挥作用;CAR-T细胞在清除肿瘤细胞的同时也会杀伤表达相同靶点的正常细胞;针对除B细胞肿瘤之外的血液肿瘤以及实体瘤而言,CAR-T细胞的有效性还有待提高。本文重点介绍如何通过CAR-T细胞结构的优化使得CAR-T细胞能够精准地识别肿瘤细胞,克服肿瘤的免疫抑制微环境来提高CAR-T细胞治疗恶性肿瘤的有效性;同时使得CAR-T细胞可以被更好地控制,使得CAR-T细胞的安全性更高。
[Abstract]:The chimeric antigen receptor T(chimeric antigen receptor T cells (T(chimeric receptor T cells) cells have moved from laboratory to clinical trial, and have achieved remarkable curative effect in the treatment of B cell malignant tumor, but in exploring the clinical study of CAR-T cell therapy for malignant tumor,There are still many difficulties and challenges: it is difficult to find tumor-specific targets to overcome their off-target off tumor effectts, and it is difficult for CAR-T cells to reach the tumor site in the treatment of solid tumors.In order to improve the immunosuppressive microenvironment, CAR-T cells can kill the normal cells with the same target while clearing the tumor cells.The effectiveness of CAR-T cells is still to be improved for blood tumors and solid tumors other than B-cell tumors.This paper focuses on how to optimize the structure of CAR-T cells so that CAR-T cells can accurately identify tumor cells and overcome tumor immunosuppressive microenvironment to improve the effectiveness of CAR-T cells in the treatment of malignant tumors.At the same time, CAR-T cells can be better controlled, making CAR-T cells more secure.
【作者单位】： 解放军第307医院造血干细胞移植科全军造血干细胞研究所;
【基金】：首都临床特色应用研究与成果推广项目(No.Z161100000516184)~~
【分类号】：R730.51
，

本文编号：1751536